FibroGen (FGEN) Tops Q4 EPS by 21c

FibroGen (NASDAQ: FGEN) reported Q4 EPS of ($0.70), $0.21 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $34.37 million versus the consensus estimate of $24.05 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• Starlink, AI Capex, rockets: deep dive into SpaceX’s first ever public report
• nVent Electric (NVT) PT Raised to $225 at UBS as Momentum Expected to Carry Through 2027
• Texas Roadhouse (TXRH) PT Raised to $235 at UBS Ahead of Q2 Earnings